Opportunity Information: Apply for PAR 23 087
Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional), PAR-23-087, is a National Institutes of Health (NIH) funding opportunity that aims to strengthen the bridge between preclinical research and clinical testing for mental health treatments. The central focus is on neurophysiological measures, meaning quantifiable signals of nervous system function, that could be shaped into practical assays for treatment development. In plain terms, the program is looking for measures that can be used reliably to test whether a potential therapy is doing something meaningful to the brain or related biological systems, and to do so in ways that make results more comparable across species and across stages of the development pipeline.
The FOA supports projects that optimize and evaluate neurophysiological measures tied to processes disrupted within individual mental disorders or shared across multiple mental disorders. A defining feature is that the work must be carried out in both healthy humans and at least one other species that is relevant to how therapies are typically developed (for example, an animal species used in preclinical screening). That cross-species requirement is meant to address a long-standing problem in psychiatric treatment development: findings that look promising in animals often fail to translate when therapies reach human testing. By pushing applicants to examine whether the same measure behaves similarly across humans and another species, the initiative tries to identify which measures are genuinely comparable and which ones diverge in ways that should caution against over-interpreting animal results.
The supported studies are described as initial proof-of-concept efforts. That means the program is not simply asking for broad exploratory work, but for targeted early-stage studies that can demonstrate whether a candidate neurophysiological measure can function as a preclinical assay for evaluating drug and device interventions and their biological targets. A successful project would help determine whether a measure is sensitive, reliable, and practical enough to be used in the screening and optimization of new therapeutic candidates, including interventions that affect specific neural circuits or physiological pathways. At the same time, the FOA explicitly values negative or differentiating information: data that show certain measures do not align between animal models and humans are still useful because they create a more defensible basis for limiting speculative extrapolations and refining which preclinical findings should be taken forward.
The practical end goal is to improve the efficiency and credibility of the therapeutic development process for mental disorders. By identifying where measures are coherent across the preclinical-to-clinical pipeline, researchers can make better decisions about which candidates to advance, how to interpret early signals of target engagement, and how to design clinical evaluations that are more likely to succeed. By also documenting inconsistencies, the program aims to reduce wasted effort on measures that cannot realistically serve as translational assays, which can ultimately speed the arrival of more effective treatments.
From an administrative standpoint, this is a discretionary NIH opportunity using a cooperative agreement mechanism, indicating substantial NIH involvement during the project, and it uses the UG3/UH3 phased structure with clinical trials being optional. The activity category is Health (CFDA 93.242). Eligible applicants are broad and include many types of U.S. government entities (state, county, city/township, special districts), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized tribal governments, and tribal organizations that are not federally recognized. Nonprofit organizations are eligible whether or not they have 501(c)(3) status, and for-profit organizations (other than small businesses) and small businesses may also apply. The FOA also highlights additional eligible groups such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, HBCUs, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). The posting lists an original closing date of 2025-06-20 and a creation date of 2023-01-13. The award ceiling and expected number of awards are not specified in the provided listing.Apply for PAR 23 087
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
- This funding opportunity was created on 2023-01-13.
- Applicants must submit their applications by 2025-06-20. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the funding opportunity called, and what is the FOA number?
The opportunity is titled "Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)" and the FOA number is PAR-23-087.
Which federal agency is offering this opportunity?
This is a National Institutes of Health (NIH) funding opportunity.
What is the main goal of this FOA?
The main goal is to strengthen the bridge between preclinical research and clinical testing for mental health treatments by developing and evaluating neurophysiological measures that can be shaped into practical, reliable assays for treatment development.
What does the FOA mean by "neurophysiological measures"?
In this context, neurophysiological measures are quantifiable signals of nervous system function that can be used to test whether a potential therapy is producing a meaningful biological effect in the brain or related systems.
What kinds of projects does this FOA support?
The FOA supports projects that optimize and evaluate neurophysiological measures tied to processes that are disrupted either within a single mental disorder or shared across multiple mental disorders, with the intent of turning those measures into usable translational assays for treatment development.
Is there a cross-species requirement?
Yes. A defining feature is that the work must be conducted in both healthy humans and at least one other species that is relevant to how therapies are typically developed (for example, an animal species used in preclinical screening).
Why does the FOA require studies in both humans and another species?
The cross-species requirement is intended to address a common translational problem in psychiatric treatment development: results that appear promising in animals often fail to translate to humans. By testing whether the same measure behaves similarly across humans and another species, the program aims to identify measures that are genuinely comparable across the pipeline.
Do the human studies need to be done in people with mental disorders?
Based on the information provided, the FOA specifies that studies must include healthy humans. It does not state in the provided description that participants must have a mental disorder.
Are these exploratory studies, or does the FOA expect proof-of-concept?
The supported studies are described as initial proof-of-concept efforts. The program is looking for targeted early-stage studies that can demonstrate whether a candidate neurophysiological measure can function as a preclinical assay for evaluating interventions and their biological targets.
What does "assay" mean in the context of this opportunity?
Here, an assay refers to a practical and reliable measure that can be used to evaluate whether a drug or device intervention is affecting a biological target or pathway in a way that is meaningful for treatment development, including supporting decisions about screening and optimization of therapeutic candidates.
What types of interventions are these assays intended to support?
The FOA specifically mentions use in evaluating drug and device interventions and their biological targets, including interventions affecting specific neural circuits or physiological pathways.
What qualities should a successful neurophysiological measure demonstrate?
Based on the description, a successful measure would help determine whether it is sensitive, reliable, and practical enough to be used for screening and optimizing new therapeutic candidates across the preclinical-to-clinical pipeline.
Does the FOA value negative results?
Yes. The FOA explicitly values negative or differentiating information. Data showing that certain measures do not align between animal models and humans are still useful because they help limit speculative extrapolations and refine which preclinical findings should be advanced.
What is the broader impact the FOA is aiming for?
The practical end goal is to improve the efficiency and credibility of therapeutic development for mental disorders by identifying measures that are coherent across development stages and species, and by documenting inconsistencies that can prevent wasted effort on measures that do not translate well.
What funding mechanism is used for this opportunity?
This opportunity uses a cooperative agreement mechanism, which indicates substantial NIH involvement during the project.
What does UG3/UH3 mean for applicants?
The opportunity uses a UG3/UH3 phased structure. Based on the provided information, this means the project is organized into phases, with NIH involvement consistent with a cooperative agreement. Specific phase transition details are not provided in the listing excerpt.
Are clinical trials required?
No. Clinical trials are optional for this FOA ("Clinical Trial Optional").
What is the activity category and CFDA number?
The activity category is Health and the CFDA listing provided is 93.242.
Who is eligible to apply?
Eligibility is broad and includes many types of entities, including U.S. government entities (state, county, city/township, special districts), independent school districts, public and state-controlled institutions of higher education, private institutions of higher education, federally recognized tribal governments, and tribal organizations that are not federally recognized. Nonprofits (with or without 501(c)(3) status), for-profit organizations (other than small businesses), and small businesses may also apply. The FOA also highlights Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, HBCUs, Tribally Controlled Colleges and Universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations).
Are foreign (non-U.S.) organizations eligible?
Yes. The eligibility list explicitly includes non-U.S. entities (foreign organizations).
Are small businesses eligible?
Yes. The eligibility description indicates that small businesses may apply.
Are for-profit organizations eligible?
Yes. The eligibility description includes for-profit organizations (other than small businesses) and also separately notes that small businesses may apply.
Are nonprofit organizations eligible even if they do not have 501(c)(3) status?
Yes. The opportunity states that nonprofit organizations are eligible whether or not they have 501(c)(3) status.
Are tribal governments and tribal organizations eligible?
Yes. Eligible applicants include federally recognized tribal governments and tribal organizations that are not federally recognized.
Are U.S. territories or possessions eligible?
Yes. The FOA highlights eligibility for U.S. territories or possessions.
What is the application deadline shown in the listing?
The posting lists an original closing date of 2025-06-20.
When was this opportunity created?
The listing shows a creation date of 2023-01-13.
Is the maximum award amount (award ceiling) provided?
No. The provided listing information states that the award ceiling is not specified.
Is the expected number of awards provided?
No. The provided listing information states that the expected number of awards is not specified.
Browse more opportunities from the same category: Health
Next opportunity: Cooperative Agreement for CESU-affiliated Partner with Great Lakes Northern Forests Cooperative Ecosystem Studies Unit
Previous opportunity: Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging findings in TBI-related dementia and/or VCID (U24 - Clinical Trials Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 23 087
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 23 087) also looked into and applied for these:
| Funding Opportunity |
|---|
| Using Just-in-Time Adaptive Interventions to Optimize Established Adolescent Mental Health Treatments (R61/R33 Clinical Trial Required) Apply for RFA MH 23 170 Funding Number: RFA MH 23 170 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R34 Clinical Trial Not Allowed) Apply for PAR 23 105 Funding Number: PAR 23 105 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional) Apply for PAR 23 102 Funding Number: PAR 23 102 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implementing and Sustaining Evidence-Based Mental Health Practices in Low-Resource Settings to Achieve Equity in Outcomes (R34 Clinical Trial Required ) Apply for PAR 23 103 Funding Number: PAR 23 103 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| PROPEL Youth and Gender (Round 3): Promoting Results and Outcomes through Policy and Economic Levers Apply for 7200AA22APS00002 03 Funding Number: 7200AA22APS00002 03 Agency: Agency for International Development Category: Health Funding Amount: $20,000,000 |
| AHRQ Small Research Projects to Advance the Science of Primary Care (R03) Apply for PA 23 115 Funding Number: PA 23 115 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional) Apply for RFA MD 23 002 Funding Number: RFA MD 23 002 Agency: National Institutes of Health Category: Health Funding Amount: $295,924 |
| Conference for Early Stage HIV/AIDS Researchers Using Nonhuman Primate Models (R13 Clinical Trial Not Allowed) Apply for PAR 22 262 Funding Number: PAR 22 262 Agency: National Institutes of Health Category: Health Funding Amount: $75,000 |
| Team Science Approaches Integrating Experimental and Computational Brain Aging Models (R21/R33 Clinical Trial Not Allowed) Apply for RFA AG 24 018 Funding Number: RFA AG 24 018 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Data Harmonization, Curation and Secondary Analysis of Existing Clinical Datasets (R61/R33 Clinical Trial Not Allowed) Apply for PAR 23 089 Funding Number: PAR 23 089 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Integrated Social and Behavior Change Apply for RFI 72052123R00004 Funding Number: RFI 72052123R00004 Agency: Haiti USAID-Port Au Prince Category: Health Funding Amount: Case Dependent |
| Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation (R21 Clinical Trial Optional) Apply for RFA EB 23 001 Funding Number: RFA EB 23 001 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Comprehensive Community Prevention and Continuum of Care (C4) Project Apply for RFI 674 23 COMPREHENSIVECAREBOTS Funding Number: RFI 674 23 COMPREHENSIVECAREBOTS Agency: South Africa USAID-Pretoria Category: Health Funding Amount: Case Dependent |
| NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) Apply for PAR 23 111 Funding Number: PAR 23 111 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Collaborative Program Grant for Multidisciplinary Teams (RM1 - Clinical Trial Optional) Apply for PAR 23 077 Funding Number: PAR 23 077 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed) Apply for PAR 23 035 Funding Number: PAR 23 035 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Consortium for Food Allergy Research: Leadership Center (UM1 Clinical Trial Required) Apply for RFA AI 22 077 Funding Number: RFA AI 22 077 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Consortium for Food Allergy Research: Clinical Research Center (U01 Clinical Trial Required) Apply for RFA AI 22 076 Funding Number: RFA AI 22 076 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required) Apply for PAR 23 090 Funding Number: PAR 23 090 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Coordinating Center on the Exposome and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD): Elucidating the Role of Social and Behavioral Determinants of Health in AD/ADRD Etiology and Disparities (U24 Clinical Trial Not Allowed) Apply for RFA AG 24 011 Funding Number: RFA AG 24 011 Agency: National Institutes of Health Category: Health Funding Amount: $5,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 23 087", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.